NEW YORK, Oct. 20, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HeartWare International, Inc. ("HeartWare" or the "Company") (NASDAQ: HTWR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether HeartWare and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On September 9, 2015, HeartWare disclosed that it had paused its MVAD clinical trial to address an MVAD controller manufacturing process issue. Then, on October 13, 2015, HeartWare announced that following the company's investigation of causes of reported adverse effects in certain clinical trial patients, HeartWare might not re-initiate enrollment in the MVAD clinical trial in November as it had previously planned.
On this news, HeartWare shares have fallen as much as $9.17, or 20.8%, during intraday trading on October 13, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP